1) resistance to chemotherapeutics
化疗药物抵抗
1.
Objective To detect the change of mutant P53 protein in cervical cancer before and after arterial interventional chemotherapy and to investigate the relationship between the protein and resistance to chemotherapeutics , therapeutic effect of arterial interventional chemotherapy.
目的 检测宫颈癌组织中突变型P53蛋白在动脉介入化疗前后的变化，探讨其与宫颈癌组织化疗药物抵抗以及动脉介入化疗疗效的关系。
2) drug resistance
药物抵抗
1.
While whether acquired drug resistance to anti-angiogenic therapies might be a feature of the TEC has not yet been reported.
目前,sorafenib等抗血管生成药物在肝癌的治疗上取得了进展,可延长患者生存期,但其疗效并不持久,通常几个月后即出现药物抵抗,肿瘤又重新生长,而其耐药机制尚不明了。
3) chemoresistance
[,keməri'zistəns]
化疗抵抗
1.
Suppression of Cyclin D1 by Hypoxia-Inducible Factor-1 via Direct Mechanism Mediates Chemoresistance in Lung Cancer Cells
低氧诱导因子-1负调控Cyclin D1的分子机制及其在肿瘤化疗抵抗中的作用研究
2.
To investigate the relation of X-linked inhibitor of apoptosis (XIAP) and second mitochondria-derived activator of caspase (Smac) signaling pathway to chemoresistance in human pancreatic cancer Panc-1 and BXPC-3 cells.
目的探讨凋亡抑制蛋白XIAP和促凋亡因子Smac在胰腺癌细胞化疗抵抗中的作用及其分子机制。
4) antitumor resistance
药物抵抗性
1.
Study on relationship between oxaliplatin antitumor resistance and ERCC1mRNA level in colorectal carcinoma cell lines;
目的分析草酸铂处理前后ERCC1 mRNA水平的变化,探讨肠癌细胞中ERCC1表达与草酸铂药物抵抗性的关联。
5) individual antit-uberculous chemotherapy
个体化抗结核药物治疗
6) chemotherapeutic agents
化疗药物
1.
Isolation and purification of breast cancer stem cells by suspension culture combined with chemotherapeutic agents;
悬浮培养联合化疗药物筛选乳腺癌干细胞
2.
Apoptosis of neuroblastoma cells induced by a combination of tumor necrosis factor-related apoptosis-inducing ligand and chemotherapeutic agents;
TRAIL联合化疗药物诱导神经母细胞瘤细胞凋亡的研究
3.
Objective To elucidate the relationship between apoptosis in vitro induced by chemotherapeutic agents and its clinical significance in primary acute leukemia(AL).
目的 研究化疗药物体外诱导原代急性白血病 (AL)细胞凋亡与临床疗效的关系。
补充资料：卵巢癌单一药物化疗
卵巢癌单一药物化疗
卵巢上皮癌的单一药物化疗，仅用一种药物进行化疗。由于其效果不如联合化疗，故目前已较少采用。但因其用法简单，宜于较长时间在门诊治疗，故多用于早期病例术后的巩固治疗，或用于因其他并发症，无法耐受联合化疗者。常用药物①马利兰(Melphalan)0.2mg/(kg·d)，5天为1个疗程，间隔3～4周；②塞替派(Thiotepa)20mg加生理盐水20ml，静推，隔日1次，共8次，总量160mg；或40mg＋生理盐水300ml，腹腔注射，每周2次，总量200mg，均间隔4周；③六甲嘧胺(hexamethylmelamine,HMM)200～250mg/m2，连续2周，或8mg/kg·d，连服3个月，间隔4周。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条